Page last updated: 2024-09-04

celastrol methyl ester and Bone Loss, Osteoclastic

celastrol methyl ester has been researched along with Bone Loss, Osteoclastic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Han, W; Jia, Y; Lu, X; Peng, J; Qian, Y; Sun, P; Wang, Y; Yang, Q; Zhang, T; Zhao, K	1
Chen, R; Hou, L; Li, X; Liang, J; Lin, X; Liu, Q; Su, Y; Wu, Z; Xu, F; Yang, X; Zhao, J	1

Other Studies

2 other study(ies) available for celastrol methyl ester and Bone Loss, Osteoclastic

Article	Year
Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo. Drug design, development and therapy, 2020, Volume: 14 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Dose-Response Relationship, Drug; Female; Humans; Macrophages; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; Pentacyclic Triterpenes; Signal Transduction; X-Ray Microtomography	2020
Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways. Drug design, development and therapy, 2021, Volume: 15 Topics: Animals; Bone Resorption; Cell Survival; Cells, Cultured; Female; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; Osteoporosis; Ovariectomy; Pentacyclic Triterpenes; Protective Agents; Transcription Factor RelA	2021

Article

Year

Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo.

Drug design, development and therapy, 2020, Volume: 14

Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Dose-Response Relationship, Drug; Female; Humans; Macrophages; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; Pentacyclic Triterpenes; Signal Transduction; X-Ray Microtomography

2020

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways.

Drug design, development and therapy, 2021, Volume: 15

Topics: Animals; Bone Resorption; Cell Survival; Cells, Cultured; Female; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; Osteoporosis; Ovariectomy; Pentacyclic Triterpenes; Protective Agents; Transcription Factor RelA

2021